DiaMedica Therapeutics Inc.
DMACDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
DMAC Earnings Report
EPS Est: $-0.19 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How DMAC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Recombinant human tissue kallikrein | Phase 3 | Acute Stroke | - | - |
DM199 | Phase 2 | Kidney Diseases | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in DiaMedica Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in DiaMedica Therapeutics Inc.'s (DMAC) pipeline across Phase 3, Phase 2. Its lead program is Recombinant human tissue kallikrein (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is DiaMedica Therapeutics Inc.'s next FDA catalyst?→
DiaMedica Therapeutics Inc.'s (DMAC) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DMAC biotech catalysts?→
Add DMAC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow DiaMedica Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.